Total Payments
$24,852
2024 Payments
$2,562
Companies
15
Transactions
37
Medicare Patients
673
Medicare Billing
$111,062
Payment Breakdown by Category
Consulting$19,050 (76.7%)
Travel$2,449 (9.9%)
Research$2,137 (8.6%)
Food & Beverage$1,190 (4.8%)
Education$26.52 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $19,050 | 8 | 76.7% |
| Travel and Lodging | $2,449 | 6 | 9.9% |
| Unspecified | $2,137 | 6 | 8.6% |
| Food and Beverage | $1,190 | 16 | 4.8% |
| Education | $26.52 | 1 | 0.1% |
Payments by Type
General
$22,716
31 transactions
Research
$2,137
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Foundation Medicine, Inc. | $6,974 | 6 | $0 (2020) |
| Eisai Inc. | $5,075 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $3,771 | 11 | $0 (2017) |
| Janssen Products, LP | $2,924 | 2 | $0 (2017) |
| Seagen Inc. | $1,875 | 1 | $0 (2021) |
| EMD Serono, Inc. | $1,750 | 1 | $0 (2020) |
| PFIZER INC. | $1,270 | 2 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $815.91 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $185.00 | 3 | $0 (2018) |
| Genentech, Inc. | $71.49 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,562 | 3 | Eisai Inc. ($2,355) |
| 2023 | $1,829 | 6 | PFIZER INC. ($1,270) |
| 2022 | $2,932 | 2 | EISAI INC. ($2,720) |
| 2021 | $1,875 | 1 | Seagen Inc. ($1,875) |
| 2020 | $8,724 | 7 | Foundation Medicine, Inc. ($6,974) |
| 2019 | $23.90 | 1 | Clovis Oncology, Inc. ($23.90) |
| 2018 | $185.00 | 3 | AstraZeneca Pharmaceuticals LP ($185.00) |
| 2017 | $6,721 | 14 | E.R. Squibb & Sons, L.L.C. ($3,771) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $191.83 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION | ||||||
| 09/03/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: NONE | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| Category: Oncology | ||||||
| 06/02/2023 | PFIZER INC. | ELREXFIO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/02/2023 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $71.49 | General |
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $50.87 | Research |
| Study: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | ||||||
| 04/17/2023 | Bayer Healthcare Pharmaceuticals Inc. | Aliqopa (Drug) | Food and Beverage | In-kind items and services | $25.01 | General |
| Category: Oncology | ||||||
| 02/16/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $411.70 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER • Category: ONCOLOGY | ||||||
| 02/14/2023 | PFIZER INC. | ELREXFIO (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ELRANATAMAB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/30/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $212.38 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER • Category: ONCOLOGY | ||||||
| 03/11/2022 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,720.00 | General |
| Category: Oncology | ||||||
| 11/12/2021 | Seagen Inc. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 12/15/2020 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 02/10/2020 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 02/01/2020 | Foundation Medicine, Inc. | FOUNDATIONACT (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2020 | Foundation Medicine, Inc. | FOUNDATIONACT (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Travel and Lodging | Cash or cash equivalent | $1,518.05 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2020 | Foundation Medicine, Inc. | FOUNDATIONACT (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Travel and Lodging | Cash or cash equivalent | $339.58 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2020 | Foundation Medicine, Inc. | FOUNDATIONACT (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Food and Beverage | Cash or cash equivalent | $217.00 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2020 | Foundation Medicine, Inc. | FOUNDATIONACT (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Food and Beverage | Cash or cash equivalent | $199.40 | General |
| Category: ONCOLOGY | ||||||
| 04/01/2019 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: Oncology | ||||||
| 05/31/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 05/31/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $70.00 | General |
| Category: Oncology | ||||||
| 05/31/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Oncology | ||||||
| 08/11/2017 | Janssen Products, LP | ZYTIGA (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 08/11/2017 | Janssen Products, LP | ZYTIGA (Drug) | Food and Beverage | In-kind items and services | $123.86 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Regeneron Pharmaceuticals, Inc. | $624.08 | 2 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION | Regeneron Pharmaceuticals, Inc. | $191.83 | 1 |
| A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | AbbVie Inc. | $50.87 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 192 | 302 | $102,966 | $27,538 |
| 2022 | 3 | 153 | 309 | $95,337 | $26,254 |
| 2021 | 3 | 170 | 368 | $113,584 | $32,442 |
| 2020 | 4 | 158 | 365 | $94,956 | $24,827 |
Total Patients
673
Total Services
1,344
Medicare Billing
$111,062
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 146 | $45,296 | $10,810 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 67 | $25,719 | $7,710 | 30.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 31 | $11,843 | $3,477 | 29.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 41 | $12,446 | $3,071 | 24.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $7,662 | $2,471 | 32.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 66 | 143 | $43,329 | $11,276 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 107 | $32,421 | $8,507 | 26.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 23 | 30 | $11,190 | $3,606 | 32.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 18 | $6,714 | $2,142 | 31.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 11 | 11 | $1,683 | $724.55 | 43.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 74 | 218 | $66,054 | $17,949 | 27.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 41 | 55 | $20,515 | $6,123 | 29.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 23 | 48 | $14,544 | $3,879 | 26.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 21 | 24 | $8,952 | $2,917 | 32.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 11 | 23 | $3,519 | $1,574 | 44.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 69 | 199 | $55,395 | $13,123 | 23.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 29 | 90 | $23,529 | $5,899 | 25.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 26 | 37 | $5,661 | $2,374 | 41.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 12 | 12 | $3,636 | $1,296 | 35.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 11 | 13 | $4,593 | $1,213 | 26.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 14 | $2,142 | $922.46 | 43.1% |
About Dr. Benedito Carneiro, MD
Dr. Benedito Carneiro, MD is a Medical Oncology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265489371.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benedito Carneiro, MD has received a total of $24,852 in payments from pharmaceutical and medical device companies, with $2,562 received in 2024. These payments were reported across 37 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($19,050).
As a Medicare-enrolled provider, Carneiro has provided services to 673 Medicare beneficiaries, totaling 1,344 services with total Medicare billing of $111,062. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Providence, RI
- Active Since 05/27/2006
- Last Updated 12/09/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1265489371
Products in Payments
- FOUNDATIONACT (Device) $5,474
- Lenvima (Drug) $5,075
- OPDIVO (Biological) $3,771
- ZYTIGA (Drug) $2,924
- PADCEV (Biological) $1,875
- FOUNDATIONONE CDX (Device) $1,500
- ELREXFIO (Drug) $1,270
- LIBTAYO (Biological) $624.08
- IMFINZI (Drug) $185.00
- Axumin (Drug) $26.52
- Aliqopa (Drug) $25.01
- Rubraca (Drug) $23.90
- XT CDX (Device) $15.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Providence
Dr. Mohammed Jaloudi, Md, MD
Medical Oncology — Payments: $86,431
Medical Oncology $86,431
Don Dizon, Md, MD
Medical Oncology — Payments: $71,072
Medical Oncology $71,072
Dr. Susan Gingrich, Md, MD
Medical Oncology — Payments: $1,897
Medical Oncology $1,897
Rochelle Strenger, Md, MD
Medical Oncology — Payments: $125.33
Medical Oncology $125.33
Dr. Kathryn Decarli, M.d, M.D
Medical Oncology — Payments: $124.80
Medical Oncology $124.80
Dr. Medhavi Gupta, M.d, M.D
Medical Oncology
Medical Oncology